Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F16%3A10331063" target="_blank" >RIV/00179906:_____/16:10331063 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11150/16:10331063 RIV/61989592:15110/16:33159410

Výsledek na webu

<a href="http://dx.doi.org/10.3109/10428194.2015.1128542" target="_blank" >http://dx.doi.org/10.3109/10428194.2015.1128542</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3109/10428194.2015.1128542" target="_blank" >10.3109/10428194.2015.1128542</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients

Popis výsledku v původním jazyce

Skin infiltration in multiple myeloma (skin MM) is a rare clinical problem. Only a few cases of skin involvement have been reported, primarily in single case reports. We analyzed and present the clinical outcomes, immunohistochemistry and cytogenetic features, and relevant laboratory data on 53 biopsy-proven skin MM cases. The median time from MM diagnosis to skin involvement was 2 years. There appears to be an overrepresentation of immunoglobulin class A (IgA) and light chain disease in skin MM. We found no correlation between CD56 negative MM and skin infiltration. We found that skin MM patients presented in all MM stages (i.e. ISS stages I to III), and there was no preferential cytogenetic abnormality. Patients with skin MM carry a very poor prognosis with a median overall survival (OS) of 8.5 months as time from skin involvement. Moreover, patients with IgA disease and plasmablastic morphology appear to have a worse OS.

Název v anglickém jazyce

Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients

Popis výsledku anglicky

Skin infiltration in multiple myeloma (skin MM) is a rare clinical problem. Only a few cases of skin involvement have been reported, primarily in single case reports. We analyzed and present the clinical outcomes, immunohistochemistry and cytogenetic features, and relevant laboratory data on 53 biopsy-proven skin MM cases. The median time from MM diagnosis to skin involvement was 2 years. There appears to be an overrepresentation of immunoglobulin class A (IgA) and light chain disease in skin MM. We found no correlation between CD56 negative MM and skin infiltration. We found that skin MM patients presented in all MM stages (i.e. ISS stages I to III), and there was no preferential cytogenetic abnormality. Patients with skin MM carry a very poor prognosis with a median overall survival (OS) of 8.5 months as time from skin involvement. Moreover, patients with IgA disease and plasmablastic morphology appear to have a worse OS.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Leukemia &amp; Lymphoma

ISSN

1042-8194

e-ISSN

—

Svazek periodika

57

Číslo periodika v rámci svazku

9

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

6

Strana od-do

2071-2076

Kód UT WoS článku

000381372800011

EID výsledku v databázi Scopus

2-s2.0-84953264965